<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605772</url>
  </required_header>
  <id_info>
    <org_study_id>FifthSunYetSen</org_study_id>
    <nct_id>NCT02605772</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Non-inferiority, Open-label Clinical Trial to Evaluate the Safety and Efficacy of GAcarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes in Chinese</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fifth Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the Safety and Efficacy of Acarbose+Saxagliptin Compared With
      Metformin+Saxagliptin in Patients With Type 2 Diabetes,100 patients with T2DM will be
      enrolled in this study.They will randomly be assigned to Acarbose+Saxagliptin or
      Metformin+Saxagliptin group.HbA1c，fasting and postprandial C-peptide will be observed before
      and after the interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants coming on study will be assigned to two groups：Acarbose+Saxagliptin and
      Metformin+Saxagliptin. It may take 1 weeks to be stabilize to a standardized dose, and then
      the investigators will follow-up the patients for 3 months.During the period,patients will be
      asked to come back to the investigators center to receive the related examination every
      month. The investigators will detect HbA1c，fasting and postprandial C-peptide before and
      after the interventions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>redunction of Hemoglobin A1c (HbA1c) Levels (%) in two groups respectively after three months intervention</measure>
    <time_frame>baseline(0 week), week twelve</time_frame>
    <description>HbA1c was measured by high performance liquid chromatography with an automated biochemistry analyzer (Roche, Switzerland).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve target of HbA1c&lt;6.5% in two groups respectively at the end of study</measure>
    <time_frame>baseline(0 week), week twelve</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Homeostasis model assessment of insulin resistance (HOMA-IR) and Homeostasis model assessment beta cell function index (HOMA-β) between two groups after three months intervention</measure>
    <time_frame>baseline(0 week), week twelve</time_frame>
    <description>HOMA-β= Fasting C-Peptide × 0.27/(Fasting Plasma Glucose-3.5 HOMA-IR = 1.5 + Fasting Plasma Glucose × Fasting CPeptide/ 2800.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>metformin+Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin 0.5g tablet Saxagliptin 5mg tablet metformin 0.5g three times a day for three months Saxagliptin 5mg one time a day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acarbose+Saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acarbose 50mg tablet Saxagliptin 5mg tablet Saxagliptin 5mg one time a day for three months acarbose 100mg three times a day for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg</description>
    <arm_group_label>acarbose+Saxagliptin</arm_group_label>
    <other_name>Glucobay</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg</description>
    <arm_group_label>metformin+Saxagliptin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg</description>
    <arm_group_label>metformin+Saxagliptin</arm_group_label>
    <arm_group_label>acarbose+Saxagliptin</arm_group_label>
    <other_name>ONGLYZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed type 2 diabetes mellitus（course of disease less than one year） who has
             not receive drug treatment.

          -  T2DM patients who has not receive drug treatment for three months at least.

          -  HbA1c for 7.5-10%.

        Exclusion Criteria:

          -  New or worsening signs or symptoms of coronary heart disease

          -  Medical history of active liver disease and kidney disease

          -  Poorly controlled hypertension（systolic blood pressure&gt;160mmHg or diastolic blood
             pressure&gt;95mmHg）

          -  A clinically important hematological disorder

          -  A history of intolerance or hypersensitivity or any contraindication to study
             medications (including saxagliptin, metformin, acarbose)

          -  Is pregnant or breast feeding or is expecting to conceive or donate eggs

          -  A medical history of drug abuse

          -  Can not be followed -up on time

          -  Endocrinological diseases（eg： hyperthyroidism、hypothyroidisn and cushing syndrom）

          -  Gastrointestinal diseases

          -  Mental disorser

          -  Hypoxic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fifth Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>liao sun</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

